Last reviewed · How we verify

Aspetar — Portfolio Competitive Intelligence Brief

Aspetar pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Platelet Rich Plasma (PRP) Platelet Rich Plasma (PRP) marketed Autologous cell therapy / Regenerative medicine Orthopedics / Sports Medicine / Regenerative Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Iffat Anwar Medical Complex · 1 shared drug class
  2. Peking University Third Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aspetar:

Cite this brief

Drug Landscape (2026). Aspetar — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aspetar. Accessed 2026-05-15.

Related